US Patent

US11752164 — Bortezomib compositions

Method of Use · Assigned to Maia Pharmaceuticals Inc · Expires 2042-09-23 · 16y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects ready-to-use liquid aqueous bortezomib compositions and methods of preparing and using them in therapeutic applications.

USPTO Abstract

The present disclosure relates to ready-to-use liquid aqueous bortezomib compositions bortezomib and pharmaceutical excipients. Other aspects include methods of preparing such ready-to-use liquid aqueous bortezomib compositions, and methods of using such ready-to-use liquid bortezomib compositions in therapeutic applications.

Drugs covered by this patent

Velcade (bortezomib) · Shilpa

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3632`	—	Velcade
`U-3632`	—	Velcade

Patent Metadata

Patent number: US11752164
Jurisdiction: US
Classification: Method of Use
Expires: 2042-09-23
Drug substance claim: No
Drug product claim: No
Assignee: Maia Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.